Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
The analyzed financial indicators exhibit predominantly negative values throughout the observed periods, reflecting ongoing operational and profitability challenges.
- Operating Profit Margin (%)
- This margin remained consistently negative from the first available data in December 2018 onwards, indicating continuous operating losses. Notably, there were significant fluctuations, with margins worsening substantially in late 2019 and further declining sharply by mid to late 2023, reaching extreme negative levels. The deepening losses suggest increased operational inefficiencies or heightened expenses relative to revenues over time.
- Net Profit Margin (%)
- Aligned closely with operating profit margins, net profit margins were also deeply negative across all periods recorded. There is a pronounced deterioration in net margins in late 2019 and exceptionally severe negative margins by 2023. The trend indicates increasing net losses, possibly driven by continued operating deficits compounded by other costs such as interest, taxes, or extraordinary items.
- Return on Equity (ROE) (%)
- ROE data is sparse but clearly reflects substantial volatility and negative returns on shareholders' equity. Early values indicate extreme negative returns, worsening dramatically in mid-2019. Subsequent quarters again reveal significant losses with large negative percentages, demonstrating that shareholders' investments have yielded considerable losses during most of this timeframe.
- Return on Assets (ROA) (%)
- ROA shows a consistently negative performance across all reported quarters. The values indicate that the company has not been able to generate positive returns from its assets at any point in the observed period. While some periods reveal slightly less negative figures, the overall trajectory points to persistent asset utilization inefficiencies and unprofitability. The declines in ROA in late 2022 and into 2023 further highlight worsening asset productivity.
In summary, the financial ratios analyzed depict a company struggling with sustained losses at both operational and net levels, coupled with poor returns on equity and assets. The trend over the periods shows increasing financial difficulties, especially pronounced from 2019 onwards, culminating in severely negative outcomes by 2023. Such negative performance metrics indicate potential concerns about the company’s financial health and operational sustainability.
Return on Sales
Return on Investment
Operating Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Operating income (loss) | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals significant volatility and a downward trend in operating income (loss) over the observed quarters. Operating income consistently reflects substantial losses, with periodic fluctuations. For example, losses peaked around March 31, 2023, exceeding -122 million US dollars, which represents one of the highest deficits recorded in the data set. Despite some quarters exhibiting slight improvements or recoveries, the general pattern is a deterioration in operating income over time.
Revenues exhibit a highly irregular pattern without a clear upward or downward trend. Initial quarters show modest revenue figures generally below 10 million US dollars, with some spikes notably in September 2020 (over 41 million US dollars) and again around mid-2022 and early 2023. However, these peaks are not sustained, with subsequent quarters showing sharp declines. The uneven revenue progression suggests challenges in stable revenue generation or episodic income sources.
Operating profit margins are consistently negative, often steeply so, indicating persistent operational losses relative to revenues. Margins frequently exceed -200% and reach extreme negative values at the end of the period, reflecting deepening inefficiencies or cost structures far exceeding income. This trend illustrates ongoing financial stress and challenges in achieving profitability.
- Operating Income (Loss)
- Consistently negative across all quarters with an intensifying downward trajectory; notable peak deficits in the most recent periods indicate worsening performance.
- Revenues
- Highly fluctuating revenues with occasional significant spikes; however, there is no evidence of sustained growth, and recent figures trend lower, indicating instability in revenue streams.
- Operating Profit Margin
- Persistently negative and often extremely adverse margins reflect ongoing operational inefficiency, with worsened losses relative to revenue as time progresses.
In summary, the financial trends demonstrate ongoing operational difficulties marked by deepening losses and inconsistent revenue flows. The company faces significant challenges in achieving financial stability and profitability based on the analyzed data.
Net Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net loss | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Loss Trend
- The net loss figures demonstrate considerable volatility with an overall increasing trend in absolute terms from March 2018 through September 2023. Starting at approximately $30 million in early 2018, the net loss reached peaks near $76 million in late 2021 and surged further, hitting a significant high around $142 million in late 2022. Although a moderate reduction is observed in 2023, the net losses remain substantially elevated compared to the earlier years, indicating ongoing financial challenges.
- Revenues Trend
- Revenues fluctuate substantially over the reported periods, with no consistent growth pattern. Initial revenues hovered around $5–10 million until late 2019, followed by a sharp drop to below $4 million in early 2020. A notable spike occurs in the third quarter of 2020, where revenues abruptly increase to over $41 million, but this is not sustained, and subsequent quarters show a return to lower revenue levels. Sporadic increases are visible, including a peak near $56 million in early 2022 and another rise close to $89 million in the third quarter of 2022, but these are interspersed with considerable declines. Overall, revenue appears quite irregular, lacking a stable upward or downward trajectory.
- Net Profit Margin Analysis
- The net profit margin remains negative throughout all periods, indicating consistent unprofitability. Margins worsen significantly over time, with values plummeting from roughly -300% in 2018 to extreme negative figures exceeding -5,000% by late 2023. This severe negativity in margin reflects the steep net losses relative to revenues and suggests the company is operating at a substantial deficit with large expenses or cost structures that are not offset by income.
- Interrelation of Revenues and Net Loss
- The data shows no clear correlation that increased revenues reduce net losses; instead, even during quarters with heightened revenue, net losses remain substantial or worsen. For example, the third quarter of 2020 features a large revenue increase but does not produce a corresponding profit, as losses spike concurrently. This points to fundamental cost or operational inefficiencies that are not mitigated by revenue growth.
- Summary
- Overall, the financial data reveals persistent and growing net losses alongside irregular and unpredictable revenue patterns. The consistent negative and worsening net profit margins emphasize the severity of the operating deficits. The lack of profit despite occasional revenue spikes indicates structural or strategic issues impacting financial performance. This situation underlines the necessity for rigorous cost management and potentially a reassessment of revenue generation strategies to move towards sustainable profitability.
Return on Equity (ROE)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net loss | ||||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Stockholders’ equity (deficit)
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends and fluctuations over the observed periods.
- Net Loss
- The net loss exhibits significant variability over time, with values consistently remaining negative, indicating ongoing net losses each quarter. Between early 2018 and late 2019, the net losses fluctuate in a range approximately between -22,000 and -32,000 thousand US dollars. From March 2020 onwards, there is increased volatility, including a sharp decrease to -3,175 thousand US dollars in September 2020, followed by a rebound to -43,930 thousand US dollars in December 2020. Subsequently, the losses deepen dramatically, reaching peaks above -140,000 thousand US dollars around late 2022 and early 2023. This pattern suggests increasing financial strain with sporadic but significant fluctuations in quarterly results.
- Stockholders’ Equity (Deficit)
- The stockholders' equity shows a declining trend from positive values at the beginning of 2018 to negative values starting mid-2019, indicating depletion of equity and possibly accumulated losses or increased liabilities. Initial quarters show equity decreasing from about 99,599 to below zero by June 2019. The equity then exhibits some recovery, notably in late 2020 and through 2021, climbing to a peak of approximately 249,020 thousand US dollars at the end of 2021. However, from early 2022, this trend reverses sharply, with equity turning negative again and declining further to reach approximately -438,801 thousand US dollars by September 2023. This drastic swing reflects significant changes in the company’s financial structure, potentially due to losses or revaluation of liabilities/assets.
- Return on Equity (ROE)
- The limited data available for ROE indicates highly negative returns throughout the recorded periods, underscoring persistent unprofitability relative to equity. Recorded ROE values range from around -77% to as low as nearly -3,125%, confirming the negative impact on shareholders’ equity. The absence of data in multiple periods suggests challenges in meaningful calculation of ROE during times of equity deficit or volatility.
Overall, the data reflects a company experiencing ongoing losses with increasingly severe net loss values in recent periods. The fluctuations and ultimate decline in stockholders’ equity underscore challenges in maintaining financial stability, with the pronounced negative equity in recent quarters highlighting significant financial distress or restructuring impact. The negative and volatile ROE values further emphasize difficulties in generating shareholder value over the analyzed timeframe.
Return on Assets (ROA)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net loss | ||||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Loss Trend
- The net loss shows considerable fluctuations over the analyzed periods, with an overall tendency toward increasing magnitude. Initially, from March 2018 to June 2020, net losses frequently exceeded $20 million, peaking around the range of $40 million in some quarters. A notable reduction occurred in September 2020 when the net loss decreased sharply to approximately $3.2 million, which appears to be an anomaly compared to surrounding periods. Following this, net losses escalated again, surpassing $60 million in late 2021 and reaching very high levels above $130 million between 2022 and 2023. This pattern indicates increasing financial challenges or intensified operational expenses over time.
- Total Assets Development
- Total assets have demonstrated a general upward trajectory from early 2018 through early 2023, rising from approximately $280 million to peaks exceeding $1 billion in 2022. While there were occasional declines in certain quarters, the trend is predominantly growth-oriented. The asset base more than tripled over the period, suggesting significant investment or asset accumulation. This growth, however, does not appear to correlate with profitability improvements, given the persistent and deepening net losses.
- Return on Assets (ROA) Analysis
- Return on assets recorded consistently negative values across the available data points. Initially, ROA ranged around -50%, slightly fluctuating but maintaining a deeply negative stance. The ROA improved temporarily during mid-2020, coinciding with the anomalous low net loss, with values near -24%, but then deteriorated progressively. By 2023, ROA reached alarming lows beyond -70%, indicating a decreasing efficiency in asset utilization relative to net income. This continuing decline reflects the mounting net losses despite asset growth, highlighting operational inefficiencies or increased expenditures not translating into asset productivity.
- Overall Financial Implications
- The data portrays a company experiencing escalating net losses over time, with an extensive increase in asset holdings that does not mitigate its financial losses. The anomalous dip in net loss during late 2020 is an outlier in an otherwise negative performance trend. The progressively worsening ROA suggests that asset expansion has not been effectively leveraged to generate positive returns. This situation signals potential concerns around cost management, revenue generation, or strategic investment outcomes that merit deeper operational and financial review.